151. Early-phenotype CAR-T cells for the treatment of pediatric cancers.
- Author
-
Meyran D, Terry RL, Zhu JJ, Haber M, Ziegler DS, Ekert PG, Trapani JA, Darcy PK, and Neeson PJ
- Subjects
- Humans, Immunotherapy, Adoptive, Phenotype, Receptors, Antigen, T-Cell genetics, T-Lymphocytes, Neoplasms therapy, Receptors, Chimeric Antigen genetics
- Abstract
Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of childhood cancers, particularly high-risk tumors that fail to respond to standard therapies. CAR-T cells have been highly successful in treating some types of hematological malignancies. However, CAR-T cells targeting solid cancers have had limited success so far for multiple reasons, including their poor long-term persistence and proliferation. Evidence is emerging to show that maintaining CAR-T cells in an early, less-differentiated state in vitro results in superior persistence, proliferation, and antitumor effects in vivo. Children are ideal candidates for receiving less-differentiated CAR-T cells, because their peripheral T-cell pool primarily comprises naïve cells that could readily be harvested in large numbers to generate early-phenotype CAR-T cells. Although several studies have reported different approaches to successfully generate early CAR-T cells, there are only a few clinical trials testing these in adult patients. No trials are currently testing early CAR-T cells in children. Here, we summarize the different strategies used to maintain CAR-T cells in an early phenotypic stage and present evidence suggesting that this approach may be particularly relevant to treating childhood cancers., Competing Interests: Disclosures DSZ received consultant fees from Amgen, Bayer, and DayOne. PJN received research funding from BMS, Roche Genentech, Compugen, and Allergan. PKD declares research funding from Myeloid Therapeutics, Prescient Therapeutics, and Juno Therapeutics. All other authors have declared no conflicts of interest., (Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF